Joseph Catanzaro
Stock Analyst at Piper Sandler
(1.98)
# 3,123
Out of 4,996 analysts
97
Total ratings
37.97%
Success rate
-6.04%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Upgrades: Overweight | $4.25 → $5 | $2.54 | +96.85% | 5 | May 20, 2025 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $2.5 → $5 | $2.90 | +72.41% | 5 | May 15, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $7.5 → $6 | $2.11 | +184.36% | 10 | Feb 28, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $50 → $45 | $19.30 | +133.16% | 3 | Feb 27, 2025 | |
| MRUS Merus | Initiates: Overweight | $84 | $68.89 | +21.93% | 1 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $105 → $110 | $112.10 | -1.87% | 5 | Feb 12, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $37 → $38 | $39.04 | -2.66% | 4 | Feb 12, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $40 → $15 | $16.05 | -6.54% | 3 | Jan 17, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $52 → $53 | $73.75 | -28.14% | 9 | Jan 10, 2025 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $7 → $10 | $2.06 | +385.44% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $57 → $70 | $43.92 | +59.38% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $2 | $0.20 | +895.02% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $2.10 | +804.76% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $7.70 | +146.75% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $3.40 | +341.18% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $42.03 | -14.35% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $6.77 | +490.84% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $12.53 | +19.71% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 | $8.93 | +291.94% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $0.91 | +394.51% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.66 | +1,707.23% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.14 | +1,654.39% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $3.48 | +187.36% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $8.53 | +111.02% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $1.69 | +1,379.29% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $5.26 | -66.73% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $19.52 | +2.46% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $1.58 | -5.06% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $8.80 | +2,172.73% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $6.59 | +431.11% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.95 | +6,215.79% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.70 | +566.67% | 3 | Apr 7, 2020 |
ImmunityBio
May 20, 2025
Upgrades: Overweight
Price Target: $4.25 → $5
Current: $2.54
Upside: +96.85%
CytomX Therapeutics
May 15, 2025
Maintains: Overweight
Price Target: $2.5 → $5
Current: $2.90
Upside: +72.41%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $2.11
Upside: +184.36%
Schrödinger
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $19.30
Upside: +133.16%
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $68.89
Upside: +21.93%
Gilead Sciences
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $112.10
Upside: -1.87%
Exelixis
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $39.04
Upside: -2.66%
Keros Therapeutics
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $16.05
Upside: -6.54%
Halozyme Therapeutics
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $73.75
Upside: -28.14%
Cardiff Oncology
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $2.06
Upside: +385.44%
Nov 7, 2024
Maintains: Overweight
Price Target: $57 → $70
Current: $43.92
Upside: +59.38%
Nov 4, 2024
Downgrades: Neutral
Price Target: $15 → $2
Current: $0.20
Upside: +895.02%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $2.10
Upside: +804.76%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $7.70
Upside: +146.75%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $3.40
Upside: +341.18%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $42.03
Upside: -14.35%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $6.77
Upside: +490.84%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $12.53
Upside: +19.71%
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $8.93
Upside: +291.94%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $0.91
Upside: +394.51%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.66
Upside: +1,707.23%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.14
Upside: +1,654.39%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $3.48
Upside: +187.36%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $8.53
Upside: +111.02%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $1.69
Upside: +1,379.29%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $5.26
Upside: -66.73%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $19.52
Upside: +2.46%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $1.58
Upside: -5.06%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $8.80
Upside: +2,172.73%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $6.59
Upside: +431.11%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $0.95
Upside: +6,215.79%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.70
Upside: +566.67%